AFATINIB FOR CHORDOMA: A phase II, single arm, multi-centre trial evaluating the efficacy of Afatinib as first-line or later-line treatment in metastatic or unresectable chordoma
Cabostar: A phase II, randomised, open-label study to assess the efficacy, safety, and pharmacokinetics (PK) of maintenance cabozantinib (XL184) plus best supportive care (BSC) versus BSC in children, adolescents and young adults (AYA) with unresectable residual osteosarcoma either at diagnosis or at first relapse after standard treatment
CGT9486-21-301 – PEAK Trial: A phase 3, randomised, open-label, multicentre clinical study of CGT9486+Sunitinib vs. Sunitinib in subjects with locally advanced, unresectable, or metastatic gastrointestinal stromal tumours
ESPRIT: ESP1/SARC025 Global Collaboration: A phase I study of a combination of the PARP inhibitor, Niraparib and Temozolomide or Irinotecan in patients with previously treated, incurable Ewing sarcoma
ImmunoSARC2: Phase I-II trial of Sunitinib plus Nivolumab after standard treatment in advanced soft tissue and bone sarcomas
PREDICT B: Predicting radiotherapy response, toxicities and quality of life related functional outcome in soft tissue sarcoma of the extremities: a prospective observational cohort study
